Related Experiment Video
Updated: Jan 23, 2026

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis
Published on: November 14, 2016
Monthly Pulse Methylprednisolone Therapy is Effective in Preventing Permanent Disease Progression in Secondary
Serkan Özakbaş1, Bilge Piri Çinar2, Didem Öz1
1Department of Neurology, Dokuz Eylül University School of Medicine, İzmir, Turkey.
Introduction:
Secondary progressive multiple sclerosis (SPMS) is the phase in which disability continues to worsen with or without accompanying attacks. Monthly methylprednisolone pulse therapy can be used in the secondary progressive phase. The purpose of the present study was to evaluate the effects of methylprednisolone pulse therapy on the basis of clinical and MRI parameters in patients with SPMS.
Methods:
This was a multi-center, examiner-blinded, prospective study. Patients with SPMS with EDSS scores of 3 or more, using one or none of azathioprine, interferon or glatiramer acetate, were evaluated. Patients were given IVMP (1 dose of 1 g IV) once a month for 24 months. EDSS scores, MRI findings, quality of life, and adverse events were evaluated.
Results:
Ninety-seven SPMS patients were included in the study. Significant decreases in new/enlarging, Gd-enhanced, and spinal lesions were observed from baseline to year 2. EDSS scores remained stable at the end of the second year. Monthly high-dose IVMP resulted in a significant decrease in attacks.
Conclusion:
This study is important in terms of emphasizing that this therapeutic option should not be overlooked, since monthly pulse therapy can halt or even reverse progression, regarded as a natural course in SPMS, albeit to a small extent.
Insights
Monthly high-dose intravenous methylprednisolone pulse therapy (IVMP) can stabilize disability and reduce new lesions in secondary progressive multiple sclerosis (SPMS). This treatment may halt or slightly reverse disease progression in SPMS patients.
Area of Science:
- Neurology
- Immunology
Background:
- Secondary progressive multiple sclerosis (SPMS) is characterized by continuous disability worsening.
- Monthly methylprednisolone pulse therapy is a potential treatment option for SPMS.
Purpose of the Study:
- To evaluate the efficacy of monthly methylprednisolone pulse therapy in SPMS patients.
- To assess the impact of IVMP on clinical and MRI parameters.
Main Methods:
- A multi-center, prospective, examiner-blinded study.
- 97 SPMS patients with EDSS scores ≥3 received 1g IVMP monthly for 24 months.
- Evaluated EDSS scores, MRI lesions, quality of life, and adverse events.
Main Results:
- Significant reduction in new/enlarging and Gd-enhanced lesions observed.
- EDSS scores remained stable over 24 months.
- Monthly IVMP significantly decreased the frequency of attacks.
Conclusions:
- Monthly pulse therapy with methylprednisolone can halt or partially reverse SPMS progression.
- This therapeutic option warrants consideration for managing SPMS.
- IVMP demonstrates a positive effect on key disease markers in SPMS.
Related Concept Videos
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Urinary Tract Calculi IV: Nutrition Therapy and Prevention
Coronary Artery Disease IV: Preventive Measures
Gene Therapy
Pulse
The pulse serves as a clinical...

